Get the Stockscreener App
4.83
0.63%
0.03
After Hours:
4.83
Zura Bio Ltd stock is traded at $4.83, with a volume of 740.73K.
It is up +0.63% in the last 24 hours and up +29.14% over the past month.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
See More
Previous Close:
$4.80
Open:
$4.72
24h Volume:
740.73K
Relative Volume:
1.09
Market Cap:
$314.06M
Revenue:
-
Net Income/Loss:
$-60.36M
P/E Ratio:
-1.0992
EPS:
-4.394
Net Cash Flow:
$-15.05M
1W Performance:
-9.21%
1M Performance:
+29.14%
6M Performance:
+327.43%
1Y Performance:
+93.20%
1-Day Range:
$4.5715
$4.95
1-Week Range:
$4.5715
$5.75
52-Week Range:
$0.97
$5.75
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
4.83 | 312.11M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio LtdOn Dec 29, co and units entered into several agreements - marketscreener.com
94E.F gains 19.90% intraday on XETRA 02 Jan 2026: €4.58 draws analyst focus - Meyka
IPO Launch: How Zura Bio Limited stock valuations compare to rivalsNew Guidance & Consistent Income Trade Recommendations - moha.gov.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
Growth Report: What makes Zura Bio Limited stock attractive to growth fundsWeekly Earnings Recap & AI Enhanced Market Trend Forecasts - Улправда
Is Zura Bio Limited stock supported by strong fundamentalsJuly 2025 Institutional & Fast Moving Stock Trade Plans - Улправда
Will Zura Bio Limited stock continue upward momentumM&A Rumor & Smart Allocation Stock Reports - Улправда
What makes Zura Bio Limited stock attractive to growth fundsEarnings Recap Report & Precise Trade Entry Recommendations - Улправда
Zura Bio Ltd Announces Director Resignation - TradingView — Track All Markets
Zura Bio Limited Announces Resignation of Arnout Ploos van Amstel as Director, Effective December 11, 2025 - marketscreener.com
Is Zura Bio Limited (94E) stock good for long term investingJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
How Zura Bio Limited (94E) stock expands through international marketsJuly 2025 Summary & Expert Approved Trade Ideas - Newser
How cyclical is Zura Bio Limited (94E) stock compared to rivalsJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - Newser
Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress - Finviz
Leerink Partnrs Estimates Zura Bio FY2025 Earnings - Defense World
Zura Bio (NASDAQ:ZURA) Upgraded at Leerink Partnrs - Defense World
Zura Bio expresses gratitude towards team in Thanksgiving message - Traders Union
How Zura Bio Limited (94E) stock compares with tech leadersLong Setup & Fast Momentum Entry Tips - newser.com
Zura Bio (ZURA) Stock Analysis Report | Financials & Insights - Benzinga
Predicting Zura Bio Limited trend using moving averagesMarket Trend Report & Safe Capital Growth Tips - newser.com
How to escape a deep drawdown in Zura Bio LimitedQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Why Zura Bio Limited (94E) stock is a strong buy callQuarterly Market Review & Expert Approved Momentum Trade Ideas - newser.com
Why Zura Bio Limited (94E) stock is upgraded to buy2025 Sector Review & Community Consensus Trade Alerts - newser.com
Building trade automation scripts for Zura Bio LimitedWeekly Investment Report & Long-Term Safe Return Strategies - newser.com
Can Zura Bio Limited stock hit record highs againGlobal Markets & High Win Rate Trade Alerts - newser.com
How supply chain issues affect Zura Bio Limited stockTreasury Yields & Daily Chart Pattern Signal Reports - newser.com
Wall Street Zen Downgrades Zura Bio (NASDAQ:ZURA) to Sell - Defense World
Risk adjusted return profile for Zura Bio Limited analyzed2025 Price Action Summary & Safe Entry Trade Reports - newser.com
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Automated trading signals detected on Zura Bio LimitedMarket Activity Report & Daily Profit Focused Stock Screening - newser.com
Clear Street initiates Zura Bio stock with Buy rating on tibulizumab potential By Investing.com - Investing.com South Africa
ZURA: Clear Street Initiates Coverage with "Buy" Rating | ZURA S - GuruFocus
Zura Bio Q3 net loss narrows despite higher R&D costs - MarketScreener
Zura Bio Ltd SEC 10-Q Report - TradingView
Zura Bio Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Zura Bio Ltd Quarterly Earnings Report | ZURA SEC FilingForm 10-Q - Stock Titan
[8-K] Zura Bio Ltd Reports Material Event | ZURA SEC FilingForm 8-K - Stock Titan
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance
Clear Street initiates Zura Bio stock with Buy rating on tibulizumab potential - Investing.com Canada
How does Zura Bio Ltd (ZURA) change from a tortoise to a hare? - Setenews
Zura Bio Limited recovery potential after sell offGold Moves & Real-Time Chart Breakout Alerts - newser.com
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):